149 related articles for article (PubMed ID: 7980110)
1. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Polman CH; Bertelsmann FW; de Waal R; van Diemen HA; Uitdehaag BM; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
[TBL] [Abstract][Full Text] [Related]
2. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
Polman CH; Bertelsmann FW; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Mar; 51(3):292-6. PubMed ID: 8129642
[TBL] [Abstract][Full Text] [Related]
3. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
Bever CT; Leslie J; Camenga DL; Panitch HS; Johnson KP
Ann Neurol; 1990 Apr; 27(4):421-7. PubMed ID: 2353797
[TBL] [Abstract][Full Text] [Related]
4. The current status of studies of aminopyridines in patients with multiple sclerosis.
Bever CT
Ann Neurol; 1994; 36 Suppl():S118-21. PubMed ID: 8017870
[TBL] [Abstract][Full Text] [Related]
5. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
Bever CT; Anderson PA; Leslie J; Panitch HS; Dhib-Jalbut S; Khan OA; Milo R; Hebel JR; Conway KL; Katz E; Johnson KP
Neurology; 1996 Dec; 47(6):1457-62. PubMed ID: 8960727
[TBL] [Abstract][Full Text] [Related]
6. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
Sheean GL; Murray NM; Rothwell JC; Miller DH; Thompson AJ
Brain; 1998 May; 121 ( Pt 5)():967-75. PubMed ID: 9619197
[TBL] [Abstract][Full Text] [Related]
7. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
[TBL] [Abstract][Full Text] [Related]
8. Aminopyridines for symptomatic treatment in multiple sclerosis.
Solari A; Uitdehaag B; Giuliani G; Pucci E; Taus C
Cochrane Database Syst Rev; 2001; 2002(4):CD001330. PubMed ID: 11687106
[TBL] [Abstract][Full Text] [Related]
9. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Flet L; Polard E; Guillard O; Leray E; Allain H; Javaudin L; Edan G
J Neurol; 2010 Jun; 257(6):937-46. PubMed ID: 20058019
[TBL] [Abstract][Full Text] [Related]
10. Aminopyridines for symptomatic treatment in multiple sclerosis.
Solari A; Uitdehaag B; Giuliani G; Pucci E; Taus C
Cochrane Database Syst Rev; 2002; (4):CD001330. PubMed ID: 12804404
[TBL] [Abstract][Full Text] [Related]
11. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
Bever CT; Young D; Anderson PA; Krumholz A; Conway K; Leslie J; Eddington N; Plaisance KI; Panitch HS; Dhib-Jalbut S
Neurology; 1994 Jun; 44(6):1054-9. PubMed ID: 8208399
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders DB; Massey JM; Sanders LL; Edwards LJ
Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
[TBL] [Abstract][Full Text] [Related]
13. 4-Aminopyridine in multiple sclerosis: prolonged administration.
Stefoski D; Davis FA; Fitzsimmons WE; Luskin SS; Rush J; Parkhurst GW
Neurology; 1991 Sep; 41(9):1344-8. PubMed ID: 1891078
[TBL] [Abstract][Full Text] [Related]
14. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Smits RC; Emmen HH; Bertelsmann FW; Kulig BM; van Loenen AC; Polman CH
Neurology; 1994 Sep; 44(9):1701-5. PubMed ID: 7936300
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Sanders DB; Howard JF; Massey JM
Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
[No Abstract] [Full Text] [Related]
16. Analysis of 3,4-diaminopyridine in human serum by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
Leslie J; Bever CT
J Chromatogr; 1989 Nov; 496(1):214-22. PubMed ID: 2556419
[No Abstract] [Full Text] [Related]
17. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.
Boerma CE; Rommes JH; van Leeuwen RB; Bakker J
J Toxicol Clin Toxicol; 1995; 33(3):249-51. PubMed ID: 7760450
[TBL] [Abstract][Full Text] [Related]
18. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
19. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Arreola-Mora C; Silva-Pereyra J; Fernández T; Paredes-Cruz M; Bertado-Cortés B; Grijalva I
Mult Scler Relat Disord; 2019 Feb; 28():117-124. PubMed ID: 30593980
[TBL] [Abstract][Full Text] [Related]
20. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.
Rossini PM; Pasqualetti P; Pozzilli C; Grasso MG; Millefiorini E; Graceffa A; Carlesimo GA; Zibellini G; Caltagirone C
Mult Scler; 2001 Dec; 7(6):354-8. PubMed ID: 11795455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
